Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy.
Analyst Price Forecast Suggests 121.74% Upside
As of December 23, 2024, the average one-year price target for Citius Pharmaceuticals is $8.16/share. The forecasts range from a low of $8.08 to a high of $8.40. The average price target represents an increase of 121.74% from its latest reported closing price of $3.68 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Citius Pharmaceuticals is 183MM. The projected annual non-GAAP EPS is 2.16.
What is the Fund Sentiment?
There are 114 funds or institutions reporting positions in Citius Pharmaceuticals. This is an decrease of 28 owner(s) or 19.72% in the last quarter. Average portfolio weight of all funds dedicated to CTXR is 0.00%, an increase of 10.09%. Total shares owned by institutions decreased in the last three months by 8.81% to 29,142K shares. 
The put/call ratio of CTXR is 0.05, indicating a bullish outlook.
What are Other Shareholders Doing?
Armistice Capital holds 7,276K shares representing 94.16% ownership of the company. In its prior filing, the firm reported owning 10,156K shares , representing a decrease of 39.58%. The firm decreased its portfolio allocation in CTXR by 21.90% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 4,140K shares representing 53.57% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 3,094K shares representing 40.04% ownership of the company. In its prior filing, the firm reported owning 3,256K shares , representing a decrease of 5.22%. The firm decreased its portfolio allocation in CTXR by 32.55% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 1,958K shares representing 25.34% ownership of the company. No change in the last quarter.
Geode Capital Management holds 1,879K shares representing 24.32% ownership of the company. In its prior filing, the firm reported owning 1,646K shares , representing an increase of 12.38%. The firm decreased its portfolio allocation in CTXR by 9.69% over the last quarter.
Citius Pharmaceuticals Background Information
(This description is provided by the company.)
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
